BridgeMD
New treatment option for Acute Ischemic Stroke
Official title NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy
ClinicalTrials.gov ID: NCT06403267
What this study is testing
What is NoNO-42?
NoNO-42 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Confirmed or suspected acute ischemic stroke (AIS) selected for intravenous thrombolysis.
- Onset (last-known-well) time to randomization time within 4.5 hours.
- Ages ≥ 18 to ≤ 90 years.
- Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) \>5.
- Confirmed or suspected symptomatic anterior circulation intracranial occlusion. Tandem extracranial carotid and intracranial occlusions are permitted.
You likely can't join if
- Large extent early ischemic changes/infarct in the ischemic territory on qualifying imaging.
- Any intracranial hemorrhage on qualifying imaging.
- Unlikely to initiate study drug administration before arterial puncture in those selected for EVT.
- Known/suspected pregnancy and/or lactation.
- Systolic blood pressure \< 90 mmHg
- Known prior receipt of NoNO-42 for any reason, including prior enrolment in this trial. 8) Severe comorbid illness with life expectancy less than 90...
See the full eligibility criteria
- Confirmed or suspected acute ischemic stroke (AIS) selected for intravenous thrombolysis.
- Onset (last-known-well) time to randomization time within 4.5 hours.
- Ages ≥ 18 to ≤ 90 years.
- Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) \>5.
- Confirmed or suspected symptomatic anterior circulation intracranial occlusion. Tandem extracranial carotid and intracranial occlusions are permitted.
- Pre-stroke independent functional status in activities of daily living as judged by the enrolling physician. Patient must be living without requiring nursing care.
- Consent process completed as per national laws and regulation and the applicable ethics committee requirements.
- Large extent early ischemic changes/infarct in the ischemic territory on qualifying imaging.
- Any intracranial hemorrhage on qualifying imaging.
- Unlikely to initiate study drug administration before arterial puncture in those selected for EVT.
- Known/suspected pregnancy and/or lactation.
- Systolic blood pressure \< 90 mmHg
- Known prior receipt of NoNO-42 for any reason, including prior enrolment in this trial. 8) Severe comorbid illness with life expectancy less than 90 days, or likely to prevent completing 90-day follow-up. 9) Long term...
The study team makes the final eligibility decision.
Where it's taking place
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- Vancouver, British Columbia, Canada
- Winnipeg, Manitoba, Canada
- Hamilton, Ontario, Canada
- Ottawa, Ontario, Canada
- Toronto, Ontario, Canada
- Saskatoon, Saskatchewan, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Calgary, Alberta, Canada; Edmonton, Alberta, Canada; Vancouver, British Columbia, Canada; Winnipeg, Manitoba, Canada; Hamilton, Ontario, Canada; Ottawa, Ontario, Canada and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.